- Home
- NPCT vs XGN Comparison
NPCT vs XGN Comparison
Compare NPCT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- XGN
- Stock Information
- Founded
- NPCT 2020
- XGN 2002
- Country
- NPCT United States
- XGN United States
- Employees
- NPCT N/A
- XGN N/A
- Industry
- NPCT Investment Managers
- XGN Medical Specialities
- Sector
- NPCT Finance
- XGN Health Care
- Exchange
- NPCT Nasdaq
- XGN Nasdaq
- Market Cap
- NPCT 306.8M
- XGN 253.9M
- IPO Year
- NPCT N/A
- XGN 2019
- Fundamental
- Price
- NPCT $10.61
- XGN $9.04
- Analyst Decision
- NPCT
- XGN Strong Buy
- Analyst Count
- NPCT 0
- XGN 6
- Target Price
- NPCT N/A
- XGN $13.67
- AVG Volume (30 Days)
- NPCT 107.1K
- XGN 388.3K
- Earning Date
- NPCT 01-01-0001
- XGN 11-04-2025
- Dividend Yield
- NPCT 9.82%
- XGN N/A
- EPS Growth
- NPCT N/A
- XGN N/A
- EPS
- NPCT N/A
- XGN N/A
- Revenue
- NPCT N/A
- XGN $63,599,000.00
- Revenue This Year
- NPCT N/A
- XGN $22.50
- Revenue Next Year
- NPCT N/A
- XGN $14.75
- P/E Ratio
- NPCT N/A
- XGN N/A
- Revenue Growth
- NPCT N/A
- XGN 14.08
- 52 Week Low
- NPCT $8.58
- XGN $2.67
- 52 Week High
- NPCT $10.63
- XGN $12.23
- Technical
- Relative Strength Index (RSI)
- NPCT 39.14
- XGN 27.81
- Support Level
- NPCT $10.62
- XGN $9.19
- Resistance Level
- NPCT $10.82
- XGN $9.74
- Average True Range (ATR)
- NPCT 0.09
- XGN 0.56
- MACD
- NPCT 0.01
- XGN -0.29
- Stochastic Oscillator
- NPCT 3.69
- XGN 3.10
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.